MX2014014520A - Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida. - Google Patents

Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida.

Info

Publication number
MX2014014520A
MX2014014520A MX2014014520A MX2014014520A MX2014014520A MX 2014014520 A MX2014014520 A MX 2014014520A MX 2014014520 A MX2014014520 A MX 2014014520A MX 2014014520 A MX2014014520 A MX 2014014520A MX 2014014520 A MX2014014520 A MX 2014014520A
Authority
MX
Mexico
Prior art keywords
isonicotinamide
phenylamino
dihydroxy
fluoro
propyl
Prior art date
Application number
MX2014014520A
Other languages
English (en)
Other versions
MX350295B (es
Inventor
Donald Bankston
Christoph Saal
Axel Becker
Clemens Kuehn
Marco Poma
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014014520A publication Critical patent/MX2014014520A/es
Publication of MX350295B publication Critical patent/MX350295B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

La invención se refiere a formas en estado sólido de N-((S)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isoni cotinamida, a procesos para su preparación y a sus usos médicos.
MX2014014520A 2012-05-30 2013-05-07 Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida. MX350295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653037P 2012-05-30 2012-05-30
PCT/EP2013/001352 WO2013178320A1 (en) 2012-05-30 2013-05-07 Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide

Publications (2)

Publication Number Publication Date
MX2014014520A true MX2014014520A (es) 2015-02-24
MX350295B MX350295B (es) 2017-09-04

Family

ID=48537929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014520A MX350295B (es) 2012-05-30 2013-05-07 Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida.

Country Status (30)

Country Link
US (1) US9260393B2 (es)
EP (1) EP2855434B1 (es)
JP (1) JP6280543B2 (es)
KR (1) KR20150022923A (es)
CN (1) CN104334530A (es)
AR (1) AR091186A1 (es)
AU (1) AU2013269994B2 (es)
BR (1) BR112014029838A2 (es)
CA (1) CA2875145C (es)
CL (1) CL2014003285A1 (es)
DK (1) DK2855434T3 (es)
EA (1) EA028059B1 (es)
ES (1) ES2592860T3 (es)
HK (1) HK1206733A1 (es)
HR (1) HRP20161135T1 (es)
HU (1) HUE028850T2 (es)
IL (1) IL235947A (es)
LT (1) LT2855434T (es)
MX (1) MX350295B (es)
MY (1) MY169266A (es)
NZ (1) NZ701103A (es)
PL (1) PL2855434T3 (es)
PT (1) PT2855434T (es)
RS (1) RS55167B1 (es)
SG (1) SG11201407842TA (es)
SI (1) SI2855434T1 (es)
TW (1) TWI570108B (es)
UA (1) UA112899C2 (es)
WO (1) WO2013178320A1 (es)
ZA (1) ZA201409426B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
KR20160138756A (ko) * 2015-05-26 2016-12-06 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
WO2018097628A2 (ko) 2016-11-25 2018-05-31 주식회사 샤인바이오 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
KR101833412B1 (ko) 2017-07-24 2018-02-28 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274572T3 (es) * 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
OA11819A (en) * 1999-01-13 2005-08-17 Warner Lambert Co 1-Heterocycle substituted diarylamines.
AU2003273192A1 (en) * 2002-05-31 2003-12-19 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
DK1802579T3 (da) 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
CN102134218A (zh) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Also Published As

Publication number Publication date
WO2013178320A1 (en) 2013-12-05
CN104334530A (zh) 2015-02-04
UA112899C2 (uk) 2016-11-10
CA2875145C (en) 2021-01-12
TWI570108B (zh) 2017-02-11
EP2855434B1 (en) 2016-06-22
LT2855434T (lt) 2016-12-12
NZ701103A (en) 2016-09-30
IL235947A0 (en) 2015-02-01
PT2855434T (pt) 2016-10-04
PL2855434T3 (pl) 2016-12-30
MY169266A (en) 2019-03-20
US9260393B2 (en) 2016-02-16
EA201401341A1 (ru) 2015-05-29
BR112014029838A2 (pt) 2017-06-27
ZA201409426B (en) 2017-05-31
AU2013269994B2 (en) 2017-04-20
AR091186A1 (es) 2015-01-14
JP6280543B2 (ja) 2018-02-14
ES2592860T3 (es) 2016-12-01
US20150152059A1 (en) 2015-06-04
TW201400459A (zh) 2014-01-01
SG11201407842TA (en) 2014-12-30
RS55167B1 (sr) 2017-01-31
HUE028850T2 (en) 2017-01-30
EP2855434A1 (en) 2015-04-08
HK1206733A1 (en) 2016-01-15
KR20150022923A (ko) 2015-03-04
JP2015518013A (ja) 2015-06-25
IL235947A (en) 2016-08-31
MX350295B (es) 2017-09-04
HRP20161135T1 (hr) 2016-11-04
CL2014003285A1 (es) 2015-03-06
CA2875145A1 (en) 2013-12-05
DK2855434T3 (en) 2016-09-12
AU2013269994A1 (en) 2015-01-22
EA028059B1 (ru) 2017-10-31
SI2855434T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
PH12015501609A1 (en) Phenicol antibacterials
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX363456B (es) Compuestos para tratar atrofia muscular espinal.
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
TW201613864A (en) Novel compounds
GB201209587D0 (en) Therapeutic compounds
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
MX343689B (es) Formulaciones combinadas de darunavir.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX341976B (es) Formulaciones de darunavir.
NZ701103A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
WO2014043252A3 (en) Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
IN2014KN02584A (es)
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration